CNS Pharmaceuticals Business Summary

CNS Pharmaceuticals, Inc. (CNSP) is a clinical-stage biopharmaceutical company dedicated to the development of novel anti-cancer drug candidates for primary and metastatic tumors of the brain and central nervous system. The company operates as a pre-revenue research entity, generating capital through equity offerings and strategic development agreements rather than product sales, with a business model centered on the eventual licensing or commercialization of its proprietary pipeline. Its primary development segments focus on three key assets: TPI 287, a blood-brain barrier (BBB) permeable abeotaxane; Berubicin, an anthracycline derivative for glioblastoma; and WP1066, an immunotherapy agent targeting the STAT3 pathway. CNSP competes in the specialized neuro-oncology market against firms such as Vera Therapeutics, NexImmune, Seagen, and Vertex Pharmaceuticals. Within this landscape, CNSP distinguishes itself as a micro-cap innovator specifically targeting the physiological limitations of the blood-brain barrier, a critical hurdle in treating aggressive CNS malignancies. The company was founded by Dr. Waldemar Priebe, a Professor of Medicinal Chemistry at MD Anderson Cancer Center and a prolific inventor with over 50 patents in oncology. As of February 2026, the firm is led by President and CEO Rami Levin, who brings nearly three decades of biopharmaceutical experience to the company’s current strategic transformation. Supporting this transition is a newly appointed executive suite including incoming CFO Steven O’Loughlin (formerly of Actinium Pharmaceuticals), CTO Eric Faulkner (formerly of Biogen and Shire), and CBO Dylan Wenke (formerly of Corbus Pharmaceuticals), all of whom were recruited in February 2026 to drive operational execution. This leadership core is complemented by Chief Medical Officer Dr. Sandra Silberman and Chief Science Officer Dr. Donald Picker. The company’s governance is overseen by Board Chairman Faith Charles and a Scientific Advisory Panel featuring Dr. Roger Stupp, the developer of the standard-of-care "Stupp Protocol" for glioblastoma, underscoring the company’s deep ties to elite academic and clinical research institutions.